Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITRO-DUR vs GONITRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a prodrug that is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylyl cyclase, increasing c GMP, leading to vasodilation primarily in veins and arteries.
Nitric oxide (NO) donor; activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation.
Prophylaxis and treatment of angina pectoris due to coronary artery disease,Heart failure (IV formulation),Hypertensive crisis (IV formulation),Anal fissures (topical ointment)
Prevention of angina pectoris due to coronary artery disease,Acute relief of angina episodes,Prophylaxis for angina before exertion or stress
Transdermal: Initial 0.2-0.4 mg/h applied once daily, titrate to 0.4-0.8 mg/h; maximum 0.8 mg/h. Remove for 10-12 hours daily to prevent tolerance.
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.
2–3 minutes (nitroglycerin); prolonged to ~30 minutes for active metabolites. Clinical context: Requires frequent dosing or continuous administration for sustained effect.
Terminal elimination half-life approximately 2-3 minutes for nitroglycerin; clinical effects cease within 30-60 minutes due to rapid redistribution and metabolism
Metabolized by glutathione S-transferases (GSTs) in the liver and erythrocytes, producing glycerol dinitrate and nitrite ions.
Extensively metabolized by mitochondrial aldehyde dehydrogenase (ALDH2) in vascular smooth muscle; also metabolized by glutathione S-transferases and cytochrome P450 (CYP3A4).
Primarily renal (>80% as inactive metabolites; <1% unchanged nitroglycerin). Minor biliary/fecal elimination.
Primarily renal: 80-90% as inactive metabolites (dinitrates, mononitrates); minor biliary/fecal (<10%)
~60% (mainly to albumin).
60% bound, primarily to plasma albumin
~3 L/kg (extensive tissue distribution).
Approximately 3.3 L/kg; extensive tissue distribution with high affinity for vascular smooth muscle
Transdermal: ~70% (relative to IV). Oral: <10% (extensive first-pass metabolism).
Sublingual: 40-60%; Oral (immediate-release): <10% due to first-pass hepatic metabolism; Transdermal: 70-90% (drug-in-adhesive); Intravenous: 100%
No dose adjustment needed for any degree of renal impairment.
No specific dose adjustment required for renal impairment. However, use with caution in severe renal dysfunction (Cr Cl <30 m L/min) due to increased risk of hypotension and methemoglobinemia.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution, consider dose reduction by 25-50% due to reduced metabolism. Child-Pugh Class C: Avoid use or use minimal effective dose (e.g., 0.2 mg/h) with close monitoring.
Child-Pugh A: No adjustment needed. Child-Pugh B: Reduce dose by 50% due to decreased clearance. Child-Pugh C: Avoid use or use with extreme caution; consider alternative therapy.
Safety and efficacy not established in pediatric patients; no standard dosing guidelines.
Sublingual: 5-10 mcg/kg/dose, maximum 0.3 mg per dose, may repeat every 5 minutes up to 3 doses. Intravenous: Start at 0.25-0.5 mcg/kg/min, titrate up to 1-5 mcg/kg/min based on response. Not recommended for children <1 year due to limited data.
Start at low end of dosing range (0.2 mg/h), titrate slowly, monitor for hypotension and dizziness. Increased sensitivity due to age-related vascular changes; may require extended nitrate-free interval (e.g., 12-14 hours).
Initiate at lower doses due to increased sensitivity: Sublingual: 0.15-0.3 mg; Transdermal: 0.2 mg/day patch; Intravenous: Start at 5 mcg/min, titrate slowly. Monitor for hypotension and syncope. Avoid sustained-release formulations due to prolonged half-life.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension, especially in hypovolemic patients; tolerance with chronic use; paradoxical bradycardia and increased angina; exacerbate hypertrophic cardiomyopathy; avoid abrupt discontinuation.
Hypotension (especially with volume depletion or diuretic therapy), reflex tachycardia, tolerance (intermittent dosing with nitrate-free interval recommended), abrupt discontinuation may cause angina rebound.
Concomitant use with PDE-5 inhibitors; severe anemia; increased intracranial pressure; hypersensitivity to nitroglycerin; acute circulatory failure; constrictive pericarditis; pericardial tamponade.
Concomitant use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil), severe anemia, increased intracranial pressure, hypersensitivity to nitrates, acute myocardial infarction with low filling pressure.
Avoid alcohol, as it can enhance hypotensive effects. No specific food restrictions, but high-fat meals may delay absorption of nitroglycerin if administered orally; transdermal route is less affected.
Avoid alcohol consumption as it may exacerbate nitroglycerin-induced hypotension and vasodilation. No specific food interactions documented; however, patients should maintain adequate hydration. High-fat meals may delay absorption, but sublingual route minimizes this effect. Grapefruit juice has no known interaction.
FDA Pregnancy Category C. First trimester: Animal studies show fetal harm, but no adequate human studies; potential risk cannot be ruled out. Second and third trimesters: Possible fetal bradycardia, hypotension, and reduced placental perfusion; avoid near term due to risk of maternal hypotension and fetal distress.
FDA Pregnancy Category C. First trimester: no increased risk of major malformations in human studies; animal studies show fetal toxicity at high doses. Second/third trimesters: risk of fetal bradycardia, hypotension, and reduced uteroplacental perfusion; avoid near term due to risk of maternal hypotension and neonatal bradycardia.
Excreted in breast milk; M/P ratio not established. Use with caution, monitor infant for hypotension or methemoglobinemia; consider pump and discard if high doses used.
Not recommended during breastfeeding. No data on M/P ratio; minimal excretion into breast milk expected but safety not established. Potential for infant hypotension and bradycardia.
No specific dose adjustments recommended; however, increased plasma volume may reduce drug concentrations; titrate to effect, avoid hypotension to maintain placental perfusion.
No standard dose adjustment required for pregnancy; use lowest effective dose. Increased plasma volume may reduce response; titrate to effect. Avoid in severe preeclampsia or volume depletion.
NITRO-DUR (nitroglycerin) transdermal patch is used for angina prophylaxis, not acute attacks. Apply to hairless area, avoid chest if possible to prevent interference with defibrillation. Rotate sites daily to prevent tolerance; remove patch for 10-12 hours daily to maintain nitrate-free interval. Contraindicated with PDE5 inhibitors (sildenafil, tadalafil, vardenafil) due to risk of severe hypotension. Monitor for hypotension, reflex tachycardia, headache.
GONITRO (nitroglycerin sublingual powder) is indicated for acute relief of angina pectoris. Administer one packet (0.4 mg or 0.8 mg) at onset of chest pain; may repeat every 5 minutes up to 3 doses. Ensure patient is seated or lying down to avoid hypotension. Do not confuse with oral spray; powder must be placed under tongue. Onset within 1-3 minutes. Common side effect: headache. Contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) within 24-48 hours due to severe hypotension. Monitor for orthostatic hypotension.
Apply patch once daily to clean, dry, hairless skin on upper arm, chest, or back.,Remove old patch before applying new one.,Keep patch on for 12-14 hours then remove for 10-12 hours to prevent tolerance.,Do not use during acute angina attack; use sublingual nitroglycerin instead.,Avoid alcohol and erectile dysfunction drugs (Viagra, Cialis, Levitra) while using this patch.,Common side effects: headache, dizziness, flushing. Report severe headache or fainting.,Do not stop abruptly; may cause rebound angina.
Take one packet at the first sign of chest pain. Empty the entire powder under your tongue and let it dissolve. Do not swallow or rinse with water.,If pain persists after 5 minutes, take a second packet. If still no relief after 5 more minutes, take a third and call 911.,Sit or lie down when taking this medication to prevent dizziness or fainting.,Avoid alcohol; it may worsen side effects like low blood pressure.,Do not use Viagra, Cialis, Levitra, or other erectile dysfunction drugs while on this medicine—serious drop in blood pressure can occur.,Headaches are common; do not stop taking the medication. Over-the-counter pain relievers may help.,Store packets at room temperature away from moisture and heat. Do not open until ready to use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITRO-DUR vs GONITRO, answered by our medical review team.
NITRO-DUR is a Nitrate Vasodilator that works by Nitroglycerin is a prodrug that is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylyl cyclase, increasing c GMP, leading to vasodilation primarily in veins and arteries.. GONITRO is a Nitrate Vasodilator that works by Nitric oxide (NO) donor; activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITRO-DUR and GONITRO depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITRO-DUR is: Transdermal: Initial 0.2-0.4 mg/h applied once daily, titrate to 0.4-0.8 mg/h; maximum 0.8 mg/h. Remove for 10-12 hours daily to prevent tolerance.. The standard adult dose of GONITRO is: Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses within 15 minutes. Prophylactic: 0.3-0.6 mg 5-10 minutes before activity. Transdermal: Apply 0.2-0.8 mg/hour patch once daily, remove at bedtime to prevent tolerance. Intravenous: Start at 5 mcg/min, titrate by 5-20 mcg/min every 3-5 minutes based on hemodynamic response; usual range 10-200 mcg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITRO-DUR and GONITRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITRO-DUR is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show fetal harm, but no adequate human studies; potential risk cannot be ruled out. Second and third trimesters: Possible . GONITRO is classified as Category C. FDA Pregnancy Category C. First trimester: no increased risk of major malformations in human studies; animal studies show fetal toxicity at high doses. Second/third trimesters: ris. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.